We found that when the patients were divided into the recurrence group and the recurrence-free group, the different genes between the two groups were concentrated in the genes such as MET, NF1, ALK, APC, PTEN, and ERBB4, involving multiple tumor suppressor genes and lung cancer-driven genes used as targets for targeted therapy. This evidence concerns the gene MET and lung carcinoma.